These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22893932)

  • 1. [Process in development of PTH, an awaited bone-density conservation agent].
    Sugimoto T
    Clin Calcium; 2012 Mar; 22(3):307. PubMed ID: 22893932
    [No Abstract]   [Full Text] [Related]  

  • 2. [Evidence for osteoporosis treatment using PTH (1-34) daily subcutaneous injection].
    Yamamoto T; Hamaya E; Sowa H
    Clin Calcium; 2012 Mar; 22(3):399-406. PubMed ID: 22370307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Monitoring bone turnover markers during treatment with the anabolic agent teriparatide; in particular, treatment using daily and weekly subucutaneous injections].
    Miyauchi A
    Clin Calcium; 2012 Mar; 22(3):387-98. PubMed ID: 22370306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evidence in the treatment of osteoporosis using weekly teriparatide injections].
    Nakamura Y
    Clin Calcium; 2012 Mar; 22(3):407-13. PubMed ID: 22370308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Update and perspectives of anabolic therapies for osteoporosis].
    Endo I; Matsumoto T
    Clin Calcium; 2012 Mar; 22(3):327-33. PubMed ID: 22370299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New bone density conservation agents for osteoporosis under research and development: PTH (1-34)].
    Endo I; Matsumoto T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():443-6. PubMed ID: 18161146
    [No Abstract]   [Full Text] [Related]  

  • 7. Teriparatide: new indication. During corticosteroid therapy: no fewer clinical fractures. Unnecessarily inconvenient.
    Prescrire Int; 2009 Aug; 18(102):159. PubMed ID: 19743573
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
    Hashimoto Y; Wakayama N; Miyauchi A
    Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis.
    Tashjian AH; Gagel RF
    J Bone Miner Res; 2006 Mar; 21(3):354-65. PubMed ID: 16491282
    [No Abstract]   [Full Text] [Related]  

  • 10. [Efficacy of teriparatide in treatment of glucocorticoid-induced osteoporosis].
    Soen S
    Clin Calcium; 2012 Mar; 22(3):315-20. PubMed ID: 22370297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Teriparatide: human recombinant parathyroid hormone (1-34) as a daily subcutaneous injection].
    Sowa H; Hamaya E; Yamamoto T
    Clin Calcium; 2011 Jan; 21(1):9-16. PubMed ID: 21187589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of parathyroid hormone (teriparatide) on bone quality in osteoporosis].
    Saito M; Marumo K
    Clin Calcium; 2012 Mar; 22(3):343-55. PubMed ID: 22370301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [hPTH(1-34) injection].
    Uzawa T; Yamauchi H
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():548-54. PubMed ID: 15035188
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect and role of teriparatide in the treatment of osteoporosis].
    Nakamura T
    Clin Calcium; 2012 Mar; 22(3):309-14. PubMed ID: 22370296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD; Hanley DA; Lorraine JK; Yu M
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of parathyroid hormone (teriparatide) on bone mass and quality in osteoporosis].
    Marumo K; Saito M
    Nihon Rinsho; 2011 Jul; 69(7):1264-9. PubMed ID: 21774369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of Latinas in Puerto Rico and the US mainland receiving teriparatide in the DANCE observational study.
    Ruff VA; Acosta A; Soto-Raices O; Sierra-Zorita R; Toro-Torres R; Rodríguez-Ginorio H; Comulada A; Chiang AY; Krohn K; Taylor KA;
    P R Health Sci J; 2014 Sep; 33(3):105-11. PubMed ID: 25244878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is Long-Term Anti-Osteoporotic Treatment Associated with Greater Risk of Cancer in People with Severe Vertebral Fractures? A Hospital-Based Cohort Study.
    Chen YC; Su FM; Cheng TT; Lai HM; Yu SF
    J Am Geriatr Soc; 2015 Nov; 63(11):2418-9. PubMed ID: 26603069
    [No Abstract]   [Full Text] [Related]  

  • 19. Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic.
    Stroup JS; Rivers SM; Abu-Baker AM; Kane MP
    Pharmacotherapy; 2007 Jun; 27(6):779-88. PubMed ID: 17542760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical diaphyseal femur fractures in patients with prolonged administration of bisphosphonate medication for osteoporosis.
    Horning JA; Czajka J; Uhl RL
    Orthopedics; 2010 Dec; 33(12):902. PubMed ID: 21117565
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.